Chronic myeloid leukaemia (CML) is a clonal stem cell disorder, characterized at the cytogenetic level by the presence of a balanced chromosomal rearrangement, the t(9;22) or Philadelphia chromosome (Ph) translocation and at the molecular level by the presence of the BCR-ABL fusion gene. 1 Several lines of evidence point to deregulated expression of the BCR-ABL tyrosine kinase as the initial genomic lesion in CML. 1 Despite the presence of a consistent genetic abnormality, however, CML patients display considerable clinical heterogeneity, the basis of which is poorly understood. This heterogeneity was well characterized by Sokal et al. 2 and is reflected 24 years later by the varying responses to treatment in chronic phase patients treated with a tyrosine kinase inhibitor. 3 We therefore used a novel ultra-high-resolution genomic screening assay to search for additional acquired genomic abnormalities that might explain this clinical heterogeneity and help to assess prognosis for individual patients.
DNA was extracted from the polymorphonuclear cells in bone marrow samples from 10 previously untreated chronic phase patients. These patients subsequently received imatinib and achieved complete cytogenetic responses, at which point further polymorphonuclear-derived DNA was prepared. Comparative genomic hybridization (CGH) was performed with a 2.1 million oligonucleotide array (NimbleGen, Milton Keynes, UK; 'HD2' 070713_HG18_WG_CGH_HX1 design). The probes on this array were selected to achieve a uniform distribution throughout the genome, with approximately one probe every 1200 bp. Each DNA sample from diagnosis was competitively hybridized against the same patient's remission sample, which avoided detection of constitutional polymorphic copy number variants and limited results to acquired leukemiarelated changes. Scanned array images were imported into NimbleScan (NimbleGen) to identify copy number aberrations (CNAs) from HD2 image and intensity data. Nexus 3 software (BioDiscovery Inc., El Segundo, CA, USA) was used to visualize the normalized segmented data. For representative CNAs the CGH result was confirmed by fluorescence in situ hybridization or quantitative real-time PCR.
All 10 CML patient samples harboured detectable genomic imbalances with an average of 53 CNAs per patient (range: 4-166). Of the 530 CNAs detected 381 (72%) were amplifications and 149 (28%) were deletions. Two hundred and fifty two CNAs (48%) involved at least one known gene. Many of the CNAs that involved single genes contained the complete gene with only small quantities of adjacent non-coding DNA. The average size of CNAs was 103 kb (range 9 kb-2 Mb). Seventy different genomic regions were aberrant in two or more patients in the cohort. Of these recurrent CNAs, amplifications of the DUSP1 and PBEF1 genes were most frequently detected; they were present in four and eight patients respectively. Other genes amplified or deleted in more than one patient included DUSP22, MAPK8IP1, MAP3K11, SUPT4H1, PTPRC, GRK6 and several members of the histone gene family.
The HD2 platform provides a sensitivity that is at least an order of magnitude greater than that of those employed in previous studies. Brazma et al. 4 used a bacterial artificial chromosome array with a much lower resolution (1 Mb) and discovered 14 common cryptic abnormalities in CML blast crisis samples that were rare in chronic phase. In a comparison between Ph-positive acute lymphoblastic leukaemia and CML, Mullighan et al. 5 used a higher-resolution 250 k SNP array and observed up to 8 CNAs per patient (range 0-8) in a cohort of 23 chronic phase CML samples, but no recurrent aberrations were detected and the authors did not specify whether samples had been taken at diagnosis or later in chronic phase. Exclusive analysis of presentation samples in our study demonstrates that many CNAs are early events in CML. Furthermore, the use of the patients' remission DNA as reference material rather than pooled normal DNA confirms all observed imbalances as disease-related.
The findings of our ultra-high-resolution screening have numerous implications. The presence of multiple genomic lesions at diagnosis supports the notion of an increased level of genomic instability in CML cells and raises the possibility that one or more aberrations in addition to BCR-ABL may dictate the CML phenotype. The considerable range in the number of CNAs present at diagnosis would be consistent with a differing level of genomic instability between individual patients. Assessment of the correlation between number of CNAs detected at diagnosis and survival in an unselected group of patients might show that high-resolution genome profiling was a good method for predicting clinical outcome in CML.
The observation that many CNAs are demarcated by the extremities of individual genes, suggests that these genes might be specific targets. Furthermore, the presence of same genetic imbalances in more than one patient in the cohort suggests a role for these genes in the pathogenesis or progression of CML. The most commonly involved gene, PBEF1, has a number of functions including roles in neutrophil proliferation 6 and in the NAD anti-apoptotic pathway. 7 Expression of PBEF1 is modulated by JUN-B, 8 which is commonly downregulated in CML cells. 1 It is therefore plausible that PBEF1 could be involved in the pathogenesis of CML. DUSP1, overrepresented in 4 of our 10 patients, might be a cooperating gene as it regulates mitogen-activated protein kinase (MAPK) activity and is itself regulated by p53 in stress responses. 9 Further study is necessary to elucidate the precise roles of these and other genes commonly subject to copy number imbalance in the CML genome.
As with most somatic rearrangements, the mechanism by which CNAs occur is unclear, but low-copy repeats such as Alu sequences, and segmental duplications (duplicons) might facilitate aberrant homologous recombination. 10 Interestingly, small duplicons are present within the 3 0 end of PBEF1 and 5 kb downstream of DUSP1. This raises the possibility that duplicons may play a role in the abnormal amplification of these genes; the existence of similar duplicons close to the normal ABL and BCR genes was recently postulated as a possible mechanism underlying the formation of the t(9;22).
Inv (11)(q21q23) The human MLL gene is frequently involved in genetic rearrangements, all of which associated with malignancies of the hematopoietic system. More than 50 rearrangements have so far been characterized at the molecular level; however, only a small portion of these MLL fusions can be recurrently identified in therapy-related malignancies. Secondary leukemias usually present as myelodysplastic syndrome or therapy-related acute myeloid leukemia (t-AML) and are characterized by the localization of the genomic breakpoint in a subregion of the MLL breakpoint cluster region, associated with specific sequence features indicating that topoisomerase II inhibition by etoposide treatment may be involved in t-AML induction. 1 Genetic rearrangements of MAML2 have first been described for a subset of salivary gland tumors. 2 Fusions between MLL and MAML2 have recently been reported for two adult leukemia patients with secondary AML and myelodysplastic syndrome. 3 Here, we describe the development of secondary T-cell acute lymphoblastic leukemia (T-ALL) in two adolescent leukemia patients. Therapy-related ALL (t-ALL) was diagnosed in a 13-year-old boy 20 months after cessation of treatment for primary AML FAB-M4 Eo. The karyotype of primary AML was 46,XY,inv(16)(p13q22),del(7)(q22), þ 8. The patient had been treated according to the standard risk group arm of the AML-BFM 98 study with high-dose cytarabine, etoposide, idarubicine and mitoxantrone. At presentation of t-ALL, he had severe breathing difficulties because of a large mediastinal mass. Surface marker expression classified the t-ALL as cortical T-cell lineage ALL with co-expression of the myeloid marker CD13, and the progenitor marker CD117. An MLL rearrangement (46,XY,inv(11)(q21q23) [20] . nuc ish 9q21 (P16x2), 11q23 (MLL prox Â 2; MLL dist Â 2)(MLL prox sept MLL dist Â 1)) with an unknown fusion partner was identified by dual-color fluorescence in situ hybridization (FISH). The patient achieved remission on the high-risk arm of the ALL-BFM 2000 study, received a hematopoietic stem cell transplant from an unrelated donor and is without evidence of disease 4 years post transplantation.
The second patient, an 11-year-old girl, presented with dacryocystitis and enlarged lymph nodes 5 years after initial diagnosis of B-cell precursor (BCP)-ALL. Flowcytometric analysis of the primary ALL showed common ALL phenotype with aberrant expression of CD66c, the myeloid marker CD13 and the progenitor marker CD117. The bone marrow karyotype was 47,XX, þ 8 [2] /46,XX [18] . FISH analysis confirmed the cyto genetic findings and trisomy of chromosome 8 on 82% of cells in the interphase analysis. Treatment according to the standard risk arm of the ALL-BFM 95 protocol led to complete remission. Three years after initial diagnosis and 11 months after the end of maintenance therapy, a late combined ALL relapse of bone marrow and central nervous system was diagnosed. Morphological remission was induced by treatment according to the
